Literature DB >> 33316289

Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.

Gregory P Takacs1, Joseph A Flores-Toro1, Jeffrey K Harrison2.   

Abstract

Chemokines are a large subfamily of cytokines known for their ability to facilitate cell migration, most notably leukocytes, throughout the body. Chemokines are necessary for a functioning immune system in both health and disease and have received considerable attention for their roles in orchestrating temporal-spatial regulation of immune cell populations in cancer. Gliomas comprise a group of common central nervous system (CNS) primary tumors that are extremely challenging to treat. Immunotherapy approaches for highly malignant brain tumors offer an exciting new avenue for therapeutic intervention but so far, have seen limited successful clinical outcomes. Herein we focus on important chemokine/chemokine receptor systems in the regulation of pro- and anti-tumor mechanisms, highlighting potential therapeutic advantages of modulating these systems in malignant gliomas and other cancers.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Chemokine; Glioblastoma; Immunotherapy; MDSC; Microglia; Tumor microenvironment

Mesh：

Substances：

Year:  2020        PMID： 33316289      PMCID： PMC8122077          DOI： 10.1016/j.pharmthera.2020.107790

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  175 in total

1.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Authors:  Michael Gobert; Isabelle Treilleux; Nathalie Bendriss-Vermare; Thomas Bachelot; Sophie Goddard-Leon; Vanessa Arfi; Cathy Biota; Anne Claire Doffin; Isabelle Durand; Daniel Olive; Solène Perez; Nicolas Pasqual; Christelle Faure; Isabelle Ray-Coquard; Alain Puisieux; Christophe Caux; Jean-Yves Blay; Christine Ménétrier-Caux
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

2.  Chemokine receptor CXCR3 promotes growth of glioma.

Authors:  Che Liu; Defang Luo; Brent A Reynolds; Geeta Meher; Alan R Katritzky; Bao Lu; Craig J Gerard; Cyrus P Bhadha; Jeffrey K Harrison
Journal:  Carcinogenesis       Date:  2010-11-03       Impact factor: 4.944

3.  Flow cytometric characterization of tumor-associated macrophages in experimental gliomas.

Authors:  B Badie; J M Schartner
Journal:  Neurosurgery       Date:  2000-04       Impact factor: 4.654

4.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Authors:  Babatunde O Oyajobi; Giovanni Franchin; Paul J Williams; Donna Pulkrabek; Anjana Gupta; Steve Munoz; Barry Grubbs; Ming Zhao; Di Chen; Barbara Sherry; Gregory R Mundy
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

5.  Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.

Authors:  Frank Szulzewsky; Andreas Pelz; Xi Feng; Michael Synowitz; Darko Markovic; Thomas Langmann; Inge R Holtman; Xi Wang; Bart J L Eggen; Hendrikus W G M Boddeke; Dolores Hambardzumyan; Susanne A Wolf; Helmut Kettenmann
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  High CXC Chemokine Ligand 16 (CXCL16) Expression Promotes Proliferation and Metastasis of Lung Cancer via Regulating the NF-κB Pathway.

Authors:  Kun Liang; Yanru Liu; Dun Eer; Jingbin Liu; Fan Yang; Ke Hu
Journal:  Med Sci Monit       Date:  2018-01-21

7.  Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.

Authors:  Cara C Schafer; Yong Wang; Kenneth P Hough; Anandi Sawant; Stefan C Grant; Victor J Thannickal; Jaroslaw Zmijewski; Selvarangan Ponnazhagan; Jessy S Deshane
Journal:  Oncotarget       Date:  2016-11-15

8.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

9.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

10.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Colin W Steele; Saadia A Karim; Joshua D G Leach; Peter Bailey; Rosanna Upstill-Goddard; Loveena Rishi; Mona Foth; Sheila Bryson; Karen McDaid; Zena Wilson; Catherine Eberlein; Juliana B Candido; Mairi Clarke; Colin Nixon; John Connelly; Nigel Jamieson; C Ross Carter; Frances Balkwill; David K Chang; T R Jeffry Evans; Douglas Strathdee; Andrew V Biankin; Robert J B Nibbs; Simon T Barry; Owen J Sansom; Jennifer P Morton
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 38.585
View more
  12 in total

1.  Developing and validating a deep learning and radiomic model for glioma grading using multiplanar reconstructed magnetic resonance contrast-enhanced T1-weighted imaging: a robust, multi-institutional study.

Authors:  Jialin Ding; Rubin Zhao; Qingtao Qiu; Jinhu Chen; Jinghao Duan; Xiujuan Cao; Yong Yin
Journal:  Quant Imaging Med Surg       Date:  2022-02

2.  Neutralizing shapeshifting pericytes enhances glioblastoma therapeutic efficacy.

Authors:  Samuel A Sprowls; Justin D Lathia
Journal:  Cell Res       Date:  2021-10       Impact factor: 46.297

Review 3.  Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma.

Authors:  Damla Isci; Giulia D'Uonnolo; May Wantz; Bernard Rogister; Arnaud Lombard; Andy Chevigné; Martyna Szpakowska; Virginie Neirinckx
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

4.  FOXN3 inhibits cell proliferation and invasion via modulating the AKT/MDM2/p53 axis in human glioma.

Authors:  Chaojia Wang; Hanjun Tu; Ling Yang; Chunming Ma; Juntao Hu; Jie Luo; Hui Wang
Journal:  Aging (Albany NY)       Date:  2021-09-12       Impact factor: 5.682

5.  Chemoattraction of Neoplastic Glial Cells with CXCL10, CCL2 and CCL11 as a Paradigm for a Promising Therapeutic Approach for Primary Brain Tumors.

Authors:  Laurence Déry; Gabriel Charest; Brigitte Guérin; Mohsen Akbari; David Fortin
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

6.  Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer.

Authors:  Xiaohua Jie; Yunshang Chen; Ye Zhao; Xijie Yang; Yingzhuo Xu; Jian Wang; Rui Meng; Sheng Zhang; Xiaorong Dong; Tao Zhang; Kunyu Yang; Shuangbing Xu; Gang Wu
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

7.  LINC00467 facilitates the proliferation, migration and invasion of glioma via promoting the expression of inositol hexakisphosphate kinase 2 by binding to miR-339-3p.

Authors:  Yin Zhang; Yaxuan Zhang; Sen Wang; Boqiang Cao; Daling Hu; Junli Jia; Yuhang Wang; Luyao Chen; Jiaming Li; Hongyi Liu; Huamin Tang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 6.832

8.  Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation.

Authors:  Amanda de Andrade Costa; Jit Chatterjee; Olivia Cobb; Elizabeth Cordell; Astoria Chao; Suzanne Schaeffer; Andrea Goldstein; Sonika Dahiya; David H Gutmann
Journal:  Neurooncol Adv       Date:  2021-12-31

Review 9.  Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.

Authors:  Magdalena Groblewska; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma.

Authors:  Guanzheng Liu; Huan Li; Wanhong Zhang; Jiefeng Yu; Xu Zhang; Runqiu Wu; Mingshan Niu; Xuejiao Liu; Rutong Yu
Journal:  J Cell Mol Med       Date:  2021-07-03       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.